Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

January 31, 2010

Study Completion Date

March 31, 2010

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG

Lumiliximab with FCR

Dose, schedule, and duration specified in protocol

Trial Locations (5)

Research Site, Birmingham

Research Site, San Diego

Research Site, Baltimore

Research Site, Columbus

Research Site, Houston